Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

By afschroeder • March 6, 2026

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellström M, Jørgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300086. Epub ahead of print. PMID: 41784015.

Tags: Hematology/Oncology, Publications

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]

Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans

Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN. Interference[...]

Using electronic patient reported outcomes (ePROs) to improve supportive care in ambulatory oncology care: a CFIR-guided pre-implementation formative evaluation

Brauer ER, Bastani R, Cheng E, Lazaro S, Wong DJ, St John MA, Ganz PA. Using electronic patient reported outcomes (ePROs) to improve supportive care[...]